免疫检查点在肝细胞癌免疫逃逸中的作用研究进展

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 706-708.

免疫检查点在肝细胞癌免疫逃逸中的作用研究进展

陈柳汛, 刘旭东, 张杨宇博, 郑辉, 梅浙川

400331 重庆医科大学临床一系八年制 2017 级(陈柳汛,刘旭东),重庆医科大学临床二系五年制 2017 级(张杨宇博,郑辉),重庆医科大学附属第二医院消化内科(梅浙川)

收稿日期:2020-08-31 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 梅浙川,Email:ykdxdeyy@public.cta.cq.cn
基金资助:
国家自然科学基金 (81972305 );重庆医科大学大学生科学研究与创新实验项目(201910631083)

Received:2020-08-31 Online:2021-06-30 Published:2021-07-19

摘要/Abstract

摘要： 肝细胞癌是我国发病率第五、死亡率第二的恶性肿瘤,严重威胁人民群众身体健康。目前免疫治疗正逐渐成为治疗肝癌有效的新方法。近年来,针对肝癌细胞免疫逃逸的信号通路研究取得了重要进展,CTLA-4、PD-1、LAG-3与TIM-3先后被证实通过不同信号通路抑制 T 细胞活化,从而促进肝癌细胞免疫逃逸。本文总结近年来免疫检查点在肝细胞癌发生发展的研究进展进行综述,并探讨靶向上述免疫检查点治疗的临床应用及前景。

陈柳汛, 刘旭东, 张杨宇博, 郑辉, 梅浙川. 免疫检查点在肝细胞癌免疫逃逸中的作用研究进展[J]. 肝脏, 2021, 26(6): 706-708.

参考文献

[1] Choi H, Cho SY, Schwartz RH. Dual effects of Sprouty 1 on TCR signaling depending on the differentiation state of the T cell. J Immunol,2006, 176: 6034-6045.
[2] Farhood B, Najafi M, Mortezaee K. CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol, 2019, 234: 8509-8521.
[3] Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res, 2017, 126:97-108.
[4] Park H, Jung JH, Jung MK,at al.Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.Hepatol Int, 2020, 14: 249-258.
[5] Safarzadeh E, Orangi M, Mohammadi H, et al. Myeloid-derived suppressor cells. Important contributors to tumor progression and metastasis. J cell physiol, 2018, 233: 3024-3036.
[6] Lu LC, Chang CJ, Hsu Ch. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma:current state and future perspectives. J hepatocell carcinoma, 2019, 6: 71-84.
[7] Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res,2018, 24: 1518-1524.
[8] Liu Z, Song Z, Sun J, et al. Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility. Int J Clin Exp Pathol, 2018, 8: 15112-15118.
[9] Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother, 2019, 68: 599-608.
[10] Izzedine H, Mateus C, Boutro C. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant, 2017, 32: 936-942.
[11] Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma:implications for genomic and immune therapies.Mol cancer, 2017, 16: 149.
[12] Xu F, Jin T, Zhu Y, et al. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res, 2018, 37: 110.
[13] Huard B, Mastrangeli R, Prigent P Bruniquel, et al. Characterization of the major histocompatibility complex class Ⅱ binding site on LAG-3 protein. Proc Nati Acad Sci USA, 1997, 94: 5744-5749.
[14] Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell, 2018, 176: 334-347.
[15] Yamamoto T, Gotoh M, Sasaki H, et al. Molecular cloning and initial characterization of a novel fibrinogenrelated gene, HFREP-1. Biochem Biophys Res Commun, 1993, 193: 681-687.
[16] Yarchoan M, Xing D, Luan L, et al. Characterization of the Immuune microenvironment in hepatocellular carcinoma. Clin Cancer Res, 2017, 23: 7333-7339.
[17] Gaglian N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cell. Nat Med, 2013, 19: 739-746.
[18] Rotte A, Jin JY, Lemaire V. Mechanistic cover view of immune checkpoint to support the rational design of their combination of cancer immunotherapy. Ann Oncel, 2008, 29: 71-83.
[19] Li Z, Li N, Li F, et al. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissue and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine, 2016, 95: e5749.
[20] Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. Haematologica, 2018, 11: 126.
[21] Zhang H, Song Y, Yang H, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappaB/IL-6/STAT3 axis. Oncogene, 2018, 27:2456-2468.
[22] Dardalhon V, Anderson AC, Kaeman J, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 2010, 185: 1383-1392.
[23] Liu F, Zeng J, Zhou S, et al. Blocking TIM-3 or/and PD-1 reverses dysfunction of tumor-infiltrating in HBV-related hepatocellular carcinoma. Cancer, 2018, 105: 439-501.
[24] Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cells IFN-gamma-mediated antitumor or immunity and suppress established tumors. Cancer Res, 2017, 71: 3540-3551.
[25] Gefen T, Castrol I, Muharemagic D, et al. A TIM-3 oligonucleotide aptamer enhances T cells functions and potentiates tumor immunity in mice. Mol Ther, 2017, 25: 2280-2288.